Passive protection experiments were conducted to determine the frequency and amounts of hyperimmune antiserum needed to block a transmissible gastroenteritis virus (TGEV) challenge infection and to identify monoclonal antibodies that are partially protective against TGEV. Hyperimmune antiserum or monoclonal antibodies were added to milk at each feeding or at selected feedings when the amount of antiserum was reduced. Three-day-old piglets were challenged with virulent virus that had been preincubated with antiserum or monoclonal antibodies. The results indicated that supplementing antiserum every other day was not efficacious for protection. Supplementing even small quantities of hyperimmune antiserum (0.5 ml) at least once a day in most cases was sufficient for piglet survival but did not prevent morbidity. Increasing the amount (Ͼ2 ml) and providing antiserum 3 times/day completely blocked the TGEV challenge infection. Two monoclonal antibodies were discovered that also provided passive protection for baby pigs. One monoclonal antibody, 5G1, had a high neutralizing titer, and the other, 6C4, was more effective in neutralizing and binding to virulent TGEV than to attenuated TGEVs. Both of these monoclonal antibodies were partially effective as supplements in milk for passive protection. Furthermore, these monoclonal antibodies were useful for boosting the efficacy of TGEV-neutralizing colostrum, which by itself was ineffective. These results show that other antigenic sites, different from the 4-well characterized epitopes on the S glycoprotein of TGEV, also are important for passive protection.
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Scours is the leading cause of preweaning illness in baby pigs (Veterinary Services, USDA: 1991, National Swine Survey. Morbidity/mortality and health management of Swine in the United States). Transmissible gastroenteritis (TGE) is a major cause of preweaning scours for neonatal piglets in the USA and worldwide. 12 The TGE coronavirus (TGEV) infects and rapidly destroys most of the enterocytes lining the small intestine, resulting in a severe malabsorptive diarrhea (scours). When the disease occurs as a sporadic epizootic outbreak, it is fatal mostly for young preweaned piglets. To reduce the cell lysis and destruction of enterocytes by TGEV, the neonatal piglet needs to frequently suckle colostrum and postcolostral milk containing virus-neutralizing antibodies. 8, 10 This intake of neutralizing antibodies by the suckling piglet provides passive protection or lactogenic immunity. 7 Monoclonal antibodies (MAbs) have been produced against TGEV proteins and used to determine the location of epitopes on the primary structure of the large spike (S) glycoprotein. The immunodominant neutralization epitope on the S protein is a complexed site termed site A consisting of 3 subsites, and it is highly conserved for strains of TGEV and for strains of porcine respiratory coronavirus (PRCV). 2, 9, 13 Three additional antigenic sites (B, C, and D) have been mapped on the S glycoprotein. The strongest neutralizing MAbs recognize site A, but sites B and D also can induce neutralizing antibodies. 4, 11 The approximate location of each epitope has been determined. Starting from the amino terminal end, these sites are site C (between residues 49 and 52), site B (between residues 97 and 144), site D (between residues 382 and 389), and site A (includes residues 538, 543, 586, and 591). 5 The terminology for these sites was previously defined. 2 It is vitally important for young pigs to ingest colostral and postcolostral milk antibodies to provide immediate protection from an acute TGEV infection. The neonatal piglets are passively protected from TGEV when they suckle immune dams. 7, 12 Frequent nursing by piglets ensures a plentiful supply of antibodies to neutralize the virus. The immunogenicity of a TGEV infection is directly correlated with viral virulence. 1, 15 Identifying MAbs that provide passive immunity will help define those epitopes that are critical for protection. Sows and gilts infected orally with virulent virus develop high levels of IgG and secretory IgA (sIgA) in their colostrum and postcolostral milk, which pro-vide passive protection for their offspring. Both the IgG and the sIgA immunoglobulin fractions of colostrum and postcolostral milk from immune dams are protective when measured amounts are fed to susceptible piglets. 14 In a previous study, a TGEV challenge infection of 3-day-old pigs was completely blocked when the challenge virus was preincubated in vitro with hyperimmune antiserum and when the antiserum was added to milk at each feeding. 19 In contrast to the protective effect of the hyperimmune antiserum, neutralizing MAbs were ineffective when fed similarly. The purpose of the present study was to extend these observations by measuring how frequently the hyperimmune antiserum needed to be given and whether preincubation of challenge virus was necessary. Moreover, 8 TGEV specific MAbs and other individual MAbs were investigated for their ability to provide passive protection.
Materials and methods
Viruses. Virulent pig-passed TGEV (Miller strain p439ϩ) a was used to prepare a stock of challenge virus as described previously. 19 The stock challenge virus had a titer of 3 ϫ 10 6 plaque-forming units (PFU)/ml on swine testicular (ST) cells. The attenuated TGEV was the 60th passage of the Miller strain on ST cells.
Virus challenge. The standard challenge dose, a 10 Ϫ3 dilution of a stock gut virus suspension, was incubated in vitro (1 hr, 37 C) with an excess of antibody as follows. For each experiment, 2 aliquots of challenge virus were thawed, mixed, and diluted 10-fold in phosphate-buffered saline (PBS). The virus was then sonicated in 2 20-sec bursts to disrupt virus aggregates. The sonicated challenge virus was further diluted in minimum essential medium (MEM) b supplemented with 2% fetal bovine serum to a final dilution of 10 Ϫ3 . The diluted virus was incubated (1 hr, 37 C) with an equal volume of hyperimmune antiserum, ascitic fluids containing MAbs, or colostral whey. TGEV-infected control piglets received challenge virus incubated (1 hr, 37 C) in an equal volume of MEM containing 2% fetal bovine serum. In lieu of an afternoon feeding, each experimental animal was given 5 ml of challenge virus plus antibody mixture or 5 ml of challenge virus plus cell culture medium (control pigs) via a stomach tube. For those piglets that were to be continuously fed hyperimmune antiserum, MAb, or colostrum, the appropriate antibody was given in the morning feeding prior to challenge and again in the evening feeding for that day and in all subsequent feedings. The pigs were observed for the onset of clinical signs, and moribund animals were euthanized during the 10-day observation period following challenge. The supplemented antibodies used had the following virus neutralizing (VN) titers: hyperimmune antiserum, 1,280; colostral whey, 1,718; MAb 5G1, 4,000. The VN titers were determined by a plaque-reduction assay with approximately 100 PFU of attenuated Miller-60 TGEV and given as the reciprocal of the highest antibody dilution that resulted in a 50% reduction of plaques. 21 For MAb 6C4, the VN titer was Ͻ2 when measured against attenuated TGEV, whereas against a virulent Miller TGEV the VN titer was 64.
The TGEV challenge virus (Miller strain) was passed only in pigs. A large batch was prepared as a small intestinal gut suspension, stabilized with fetal bovine serum, aliquoted, and stored in liquid nitrogen. 19 Supplemental hyperimmune antiserum. MAbs. and colostrum. The preparation of the hyperimmune anti-TGEV serum was described previously. 19 The pregnant sow was exposed to virulent TGEV twice, contact exposed by its piglets, and finally given 2 additional doses of virulent virus.
Monoclonal antibodies directed against the S glycoprotein were prepared by standard methods using the semipurified Miller strain of TGEV. 18 Primary hybridomas that were secreting antibody were cloned twice and administered intraperitoneally to pristine-primed Balb/c mice. The resultant ascites fluid was collected, pooled, clarified (2,000 ϫ g for 15 min), heat inactivated (30 min, 56 C), and stored at Ϫ20 C.
To obtain colostral whey, a pregnant gilt (no. 69) that was seronegative for TGEV-neutralizing antibody was inoculated oral/nasally at 8, 4, and 2 wk before farrowing with PRCV Ind-89. 20 Colostrum (2.5 liters) was collected the day of farrowing. The colostrum was centrifuged (5,500 ϫ g, 15 min, 4 C), and the whey was divided into 10-ml aliquots, heat inactivated (30 min, 56 C), and stored at Ϫ20 C.
Piglet housing and feeding. All sows before farrowing or cesarean delivery were seronegative for TGEV-neutralizing antibody. The piglets from these sows were housed in individual plexiglass isolators in a room maintained at 35 C. These isolation chambers were kept under negative pressure to prevent cross-contamination by aerosolized virus. Sterile milk replacer c was used to feed the piglets. Their daily ration of milk was divided into three 60-ml feedings during the first 3 days after farrowing and was gradually increased to 100 ml/feeding by day 13 (10 days after piglets were challenged). All experimental protocols used for these studies were approved by the Animal Care and Use Committee at the National Animal Disease Center, Ames, Iowa.
Radioimmunoassay. A radioimmunoassay (RIA) was modified slightly from the procedure that was previously described. 21 A 96-well polyvinyl U plate d was coated overnight at 4 C with 100 l of TGEV antigen. The antigen, normalized to bind about 2,000 cpm using MAb 4F6, was either the Miller-60 supernatant virus or a 10% (w/v) TGEV-infected intestinal homogenate. After removing the unbound virus, a blocking solution of 0.5% bovine serum albumin (BSA) was incubated for 1 hr at room temperature. After rinsing, 25 l of a MAb solution (dilutions from 1:8 to 1: 32) was added and incubated for 3 hr at room temperature. The wells were rinsed, and 100 l containing 20,000 cpm of 125 I-labeled anti-mouse F(ab) 2e was added and incubated overnight at 4 C. The wells were rinsed 5 times, dried, cut out, and counted individually in a gamma counter. f Competitive RIA. Competitive RIAs (cRIAs) were carried out as described previously using standard MAbs that define the 4 known antigenic sites on the TGEV S glycoprotein. 2 The standard MAbs were 1D.B3 and 6A.C3 for TGEV site A, 1B.H11 for site B, 5B.H1 for site C, and 1D.G3 for site D. These MAbs were purified by high-pressure liquid chro- matography from ascites fluids and were labeled with 125 I. 6 The inhibition for binding of 125 I-labeled MAb to purified virus by unlabeled MAbs was studied in a 1-step cRIA. TGEV-coated polyvinyl plates d were incubated with 5% BSA in PBS for 2 hr at 37 C. Then 5-fold dilutions of each unlabeled MAb in PBS containing 0.1% BSA were mixed with a 125 I-labeled MAb (5 ϫ 10 5 cpm/well, specific activity 10 7 cpm g immunoglobulin) in each well and incubated for 2 hr at 37 C. Plates were washed 6 times with PBS containing 0.1% BSA and 0.05% Tween 20, and the wells were dried and counted individually in a gamma counter.
Results

Protective effects of hyperimmune anti-TGEV serum
Frequency of supplementation. In previous experiments, naive piglets were completely protected from TGEV when the challenge virus was preincubated (neutralized) with hyperimmune antiserum and when each feeding of milk was supplemented with the hyperimmune antiserum. These experimental results were repeated, but less antiserum (1 or 2 ml) was provided in the milk at each feeding (3 times/day). Piglets supplemented with 2 ml/feeding showed no clinical signs during the 10-day postchallenge observation period (Table 1 ). Piglet no. 3 supplemented with 1 ml/ feeding showed mild signs. On days 4 and 5 postchallenge, the perianal region of this pig was soiled and stained, but its appetite remained vigorous throughout the observation period and there were no clinical signs beyond day 5.
As the level of antiserum supplementation was reduced gradually, the clinical effects and mortality resulting from the TGEV challenge increased (Table 1) . Four pigs were supplemented with 1 ml or 0.5 ml of antiserum at the morning feeding only (1 time/day). One of the 4 pigs showed diarrhea and vomiting on day 2 and died on day 3 postchallenge. The other 3 pigs had good appetites throughout the observation period and mild clinical signs (a soiled perianal region) for 1-4 days before recovering. Another group of 2 piglets was supplemented with antiserum in the morning of day 1 postchallenge and then on alternating days. Both of these pigs had diarrhea on day 2; one pig died on day 4 and the other pig was euthanized on day 4 postchallenge. Piglet no.10 was challenged similarly with preincubated gut virus, but no antiserum was provided at its feedings. This pig showed clinical signs in 24 hours and died on day 5 postchallenge. Piglet no.11 was a control pig given the identical dose of challenge virus, but the challenge virus was incubated with tissue culture medium instead of antiserum. This pig had diarrhea at the end of day 1 and died on day 2 postchallenge. These data demonstrate that gut virus is infectious after preincubation with antiserum even though it was not detectable by in vitro culturing on ST cells.
Eliminating the preincubation step. The need to preincubate the challenge virus with antiserum was investigated. Four piglets from one litter were used as controls to demonstrate the potency of the challenge virus; 3 pigs were given the standard virus dose (5 ml of 10 Ϫ3 dilution), and a fourth piglet was given a 1,000-fold lower dose (5 ml of 10 Ϫ6 dilution). The milk fed to these control piglets was not supplemented with antiserum. All 3 of the control pigs (given the standard dose of challenge virus) died on days 4 or 6 postchallenge, and the fourth piglet (given a 1,000-fold lower dose) died on day 6 postchallenge. In contrast, 3 piglets from the same litter (Table 2, group II) were challenged with the standard virus dose but at each feeding their milk was supplemented with 4 ml of antiserum. Two of these piglets showed a watery diarrhea on day 4 postchallenge, and the third had milder signs (slight anorecia and lethargy). By day 10 postchallenge, 2 of the antiserum-supplemented pigs had recovered and were normal, but the third pig in this group still remained lethargic. Thus, antiserum alone when supplemented at 3 times/day could ameliorate the lethal effects of TGEV challenge without the need for in vitro incubation of the virus with antiserum before the challenge.
One additional piglet from this litter was used to Partial passive protection from TGEV challenge infection repeat the scheme for complete protection ( Table 2 , group I). The challenge virus was preincubated with antiserum for 1 hour at 37 C, and antiserum was supplemented at each feeding. No clinical signs following challenge were seen in this pig. It was apparently not infected with TGEV; its serum at day 21 postchallenge was negative for TGEV antibody, whereas the antiserum-supplemented pigs in group II were seropositive at 21 days postchallenge.
Partial passive protection with MAbs
The TGEV-specific MAbs were tested as supplements in the milk during a series of experiments. For each experiment, control piglets were included to ensure that the standard challenge dose was lethal for young pigs. A cocktail consisting of 8 MAbs ϩ complement (different amounts of each ascitic fluid based the total available for each antibody) was used to preincubate the challenge virus, and the MAb cocktail minus the complement was given at each feeding (3 times/day). The cocktail of 8 MAbs had a strong effect in passively protecting the piglets ( Table 3 ). Four of the 5 piglets in this group survived the TGEV challenge. One of these 4 pigs was normal throughout the 10-day observation period. The other 3 surviving pigs had diarrhea and recovered. The fifth pig in this group became lethargic on day 2, had diarrhea on day 3, and was euthanized on day 4.
To focus on the most efficacious MAbs, the 8 MAbs were divided into 2 smaller cocktails of 4 MAbs each ( Table 3 , groups II and III). The subcocktail used with group II piglets contained MAb 6C4, which binds more strongly to virulent TGEV, and 3 other strong neutralizing MAbs and thus was predicted to provide the best protection. However both smaller subcocktails were ineffective in protecting the piglets ( Table 3 ). The reason why neither subcocktail was efficacious is still not understood.
The MAbs 6C4 (strongest against virulent viruses) and 5G1 (a strong neutralizing antibody) were tested for passive protection both together as a mix and individually (Table 3 , groups IV, V, and VI). Both MAbs partially protected piglets either individually or when given together as a 2-MAb cocktail. These MAbs did not prevent morbidity (all surviving piglets showed clinical signs) but did partially protect piglets in a TGEV challenge system that is very stringent, i.e., all control pigs (n ϭ 55) died or were euthanized at this dose of challenge virus.
Characterization of MAbs 5G1 and 6C4
Monoclonal antibody 5G1 reacts with a neutralizing epitope on the TGEV S glycoprotein, GP 200 (data not shown). Competitive blocking assays indicated that the target epitope for 5G1 is not one of the 4 major epitopes, i.e., sites A, B, C, and D described for TGEV. Figure 1 shows the results of a representative competitive blocking assay with 5G1 and the site A-specific MAbs 1D.B3 and 6A.C3. Similar assays with MAbs specific for sites B, C, and D also resulted in no competitive blocking with MAb 5G1 (data not shown). Monoclonal antibody 5G1 was selected for these supplementation/feeding experiments because it is specific for GP-200 and because it has a high neutralizing titer.
Monoclonal antibody 6C4 is a weak neutralizing antibody and is specific for the TGEV S glycoprotein. It was included in the feeding experiments because it has relatively stronger binding against virulent TGEV than against attenuated TGEVs. Monoclonal antibody 6C4 bound about 8 times more strongly to the Miller gut virus than to the attenuated Miller-60 virus (Table 4 ). Three other MAbs (4F6, 4E1, and 1A6), all with different TGEV protein specificities, generally bound to the TGEV antigen more strongly than did MAb 6C4, and these MAbs also bound to attenuated and virulent TGEVs at about equal levels. Competitive blocking experiments have not been carried out for MAb 6C4 so its relationship to sites A, B, C, and D is unknown.
Passive protection by supplementing colostral whey with MAbs or antiserum
High-titer colostral whey from a PRCV-exposed gilt was used to preincubate the challenge virus, and 10 ml of this colostrum was given at the feeding before challenging the piglets and at each subsequent feeding of these pigs (3 times/day). Despite supplementing with colostral antibody, all 5 piglets in this group developed clinical signs and died or were euthanized during the 10-day observation period ( Table 5 , group I). Additional piglets were used to determine the effects of further supplementation of the same colostrum with either a 6C4 ϩ 5G1 MAb mix or with hyperimmune anti-TGEV serum ( Table 5 , groups II and III). The challenge TGEV was preincubated with 10 ml colostrum ϩ 6C4 ϩ 5G1, and this supplement was added with each feeding for 3 piglets. Two of these piglets were completely normal postchallenge, showing no clinical signs, and they were serologically negative at 21 days postchallenge. The third piglet was lethargic on day 2 postchallenge; it was slow to eat for the rest of the postchallenge observation period, but no signs of diarrhea were observed. This pig was euthanized, and the other 2 piglets were weaned at 2 weeks of age.
Colostrum also was used in conjunction with the hyperimmune antiserum. For the 2 pigs in group III, the challenge virus was preincubated with colostrum ϩ antiserum, and colostrum ϩ antiserum was given at each feeding. Both group III piglets were normal, without clinical signs, during the postchallenge period, and neither seroconverted at 21 days postchallenge.
Discussion
Suckling piglets are protected from TGEV when a plentiful supply of colostrum and milk are available from an immune dam. The quality of the antibody in the milk is important because infection with virulent TGEV induces protective antibodies. 3, 14 To study the parameters of protection, a passive protection model was reconstructed by challenging individual piglets with a lethal dose of TGEV and then supplying the infected piglets with adequate quantities of hyperimmune antiserum. When fully virulent challenge virus (no in vitro preincubation) was given to 3-day-old piglets at midday after giving these piglets 4 ml of anti-serum at the morning feeding and at each feeding for the next 10 days, the piglets became lethargic and had diarrhea but recovered from the infection. Thus, protective critical antibodies were present in the hyperimmune antiserum, and sufficient quantities of antibody were supplied continuously to the piglets with 3 feedings/day so that the virus infection was held in check.
Similarly, in a previous study (Haelterman EO: 1963, 17th World Vet Congr 1:615-618), the slow feeding of antiserum from convalescent pigs (given with 2 feedings/day) provided piglets with resistance to an experimental TGEV challenge. Moreover, the piglets that suckled immune sows became susceptible to TGEV challenge in as little as 4 hours after they were removed from the sow, and thus it was concluded that a continuous supply of immune milk provided by frequent nursing was necessary for protection.
To further clarify how often hyperimmune antiserum needed to be supplied to individual piglets in a controlled experiment, the frequency of antiserum supplementation in the feedings was gradually reduced. For these experiments, the challenge virus was preincubated with the antiserum in vitro. After this preincubation step, the severity of the challenge dose was reduced but, in the absence of supplemental antiserum the virus remained infectious for the 3-day-old piglets and was still lethal, as shown by the results for pig no.10 and other sick piglets in Table 1 . Using this preincubation model, the results based on surviving pigs indicated that 1) antiserum needs to be supplemented in milk, 2) supplementing antiserum every other day is not efficacious for protecting the piglets, 3) supplementing antiserum once a day is marginally effective, and 4) supplementing with Ͼ1 ml of hyperimmune anti-TGEV serum at each feeding (3 times/day) is effective in protecting piglets if the challenge virus is preincubated with the antiserum. Supplementing with Ͼ2 ml (3 times/day) completely blocks infection with preincubated challenge virus. Thus, these results are in general agreement with those for the earlier study (Haelterman EO: 1963 , Proc 17th World Vet Congr 1: 615-618), but the results show that supplementing with antiserum at 4-hour intervals would be unnecessarily excessive for passive protection.
The feeding model also was used to identify MAbs that provide passive protection for baby pigs. These MAbs will help to define the critical epitopes on virulent TGEVs that induce protective antibodies. Two MAbs provided partial passive protection for piglets. Monoclonal antibody 5G1 had a high neutralizing titer for TGEV but was not directed to any of the 4 known antigenic sites (C, B, D, and A) on the S glycoprotein. The other MAb, 6C4, did not have a high neutralizing titer against TGEV but was more effective in neutral-izing and in binding to virulent TGEV than to attenuated TGEVs. Both of these MAbs were partially effective as supplements in milk for passive protection and were useful in boosting the efficacy of the colostrum, which was ineffective by itself. The combination of PRCV-induced colostrum supplemented with MAbs 6C4 and 5G1 provided good passive protection for baby pigs. These results show that TGEV determinants on the S glycoprotein other than the 4 well-characterized epitopes C, B, D, and A are important for the passive protection.
In similar passive protection feeding experiments, hyperimmune antiserum from pigs inoculated with recombinant adenovirus Ad-TS-8 was used to protect miniswine for up to 5 days postchallenge. 17 In this instance, passive protection also occurred in the absence of site A and D antibodies because recombinant Ad-TS-8 only expresses a portion of the amino-terminal end of the S glycoprotein.
In a previous study attempting to identify critical epitopes, 19 the same passive protection feeding model was used but with different MAbs. In that study, 3 MAbs with the highest neutralizing titers were used; one MAb (4F6) was site A specific, another (5D5) was S glycoprotein specific but its epitope was not 1 of the 4 well-characterized sites (C, B, D, or A), and the third (1A6) was M protein specific with a very high neutralizing titer (59,000) when mixed with complement. However, none of these 3 MAbs, tested individually or in mixtures, were effective in providing passive protection from a TGEV challenge. Thus, MAbs with highest in vitro VN titers do not necessarily provide for passive protection. The question as to the importance of in vitro neutralization remains unresolved for TGE because, in the present study, 1 MAb (5G1) providing partial passive protection has a high VN titer whereas the other MAb (6C4) has a low VN titer and only neutralizes virulent TGEV.
In another passive protection experiment, antiserum from a single inoculation with a recombinant adenovirus (Ad-TS-9) expressing a full length TGEV S gene was effective in protecting miniswine from challenge virus. 16 The recombinant adenovirus may have helped to enhance the immunity against TGEV because, generally, attenuated TGEVs are not by themselves efficacious in providing for passive immunity. 1, 15 Although the S gene for Ad-TS-9 was derived from an attenuated TGEV, the antiserum induced by a single inoculation with Ad-TS-9 proved to be passively protective for miniswine.
Using another experimental approach, the epitope specificity of antibodies in colostrum and milk of sows vaccinated with virulent TGEV was studied. 3 In this case, the relative amounts of specific antibodies were measured by cRIAs with MAbs directed to the 4 known antigenic sites on the S protein and with MAbs specific for the M and N proteins. These cRIAs indicated that neutralizing site A on the S protein was dominant in colostrum and milk and was correlated with passive protection from a TGEV challenge. Thus, not all site A MAbs are protective (e.g., MAb 4F6), but some particular site A antibodies in polyclonal serum are important for passive protection.
Accordingly, cRIA experiments can be used to confirm the importance of critical antibodies defined by the epitopes for MAbs 6C4 and 5G1. Using colostrum and milk that is known to be either passively protective or not to be protective in cRIAs, then one can quantitate the levels of antibodies in this colostrum and milk that compete with MAb 5G1 or 6C4 or other MAbs of known site specificity.
